



## **Cynbiose and Motac Announce Strategic Partnership to Accelerate Central Nervous System Research**

August 29, 2024 - Lyon, France and Bordeaux, France – **Cynbiose**, a leading preclinical contract research organisation (CRO) specialised in non-human primate (NHP) models, and **Motac Neuroscience**, a pioneer in neurodegenerative disease research and drug development, are pleased to announce a **strategic partnership aimed at accelerating the development of novel therapeutics for central nervous system diseases**.

This partnership combines Cynbiose's world-renowned expertise in developing and utilising NHP models with Motac Neuroscience's cutting-edge research in neurodegenerative diseases, including Parkinson's, Alzheimer's, and other related disorders. The two companies will collaborate on a continuum of preclinical studies from early proof-of-concepts to IND-enabling toxicity studies, in order to speed up the development of new therapeutic approaches to neurological diseases.

**This strategic partnership is poised to make significant contributions to neurodegenerative disease research, fostering innovation and accelerating the development of new treatments that can potentially change lives.**


*"We are thrilled to partner with Motac Neuroscience, a leader in neurodegenerative research. This collaboration underscores our commitment to advancing scientific knowledge and developing effective therapies for these devastating diseases,"* said Dr. **Hugues Contamin, CEO of Cynbiose**. *"By combining our expertise, we can significantly enhance the preclinical development process to and bring hope to patients faster."*

*"Our partnership with Cynbiose marks a significant milestone in our mission to develop groundbreaking treatments for neurodegenerative diseases,"* said **Dr. Erwan Bezar, CSO of Motac Neuroscience**. *"Cynbiose's unparalleled expertise in NHP models will be instrumental in validating our research and advancing promising candidates to the next stage of development."*

**Key Objectives of the Partnership:**

1. **Enhanced Regulatory Environment:** Leverage Cynbiose's advanced QMS environment to provide regulatory-ready preclinical studies, offering critical insights for advancing novel treatments.
2. **Accelerated Drug Development:** Utilise Motac's innovative research methodologies to identify and validate new therapeutic targets, accelerating the pathway from discovery to clinical trials.
3. **Collaborative Research Programs:** Launch joint research initiatives that combine both organisations' scientific expertise and technological capabilities to address the most pressing challenges in central nervous system disease research.
4. **Global Impact:** Strengthen the global research community's efforts to combat central nervous system disease by sharing findings and advancements through collaborative publications and presentations at international scientific conferences.
5. **Focus on animal welfare and ethics:** Thanks to its worldwide footprint, the partnership has access to brand-new animal facilities in both France and China, enforcing the highest industry standards of animal welfare in all their research sites.

**A unique Preclinical and regulatory package**



## **About Cynbiose**

Cynbiose is a premier preclinical CRO specialised in the use of non-human primate models for the study of human diseases. With focuses on translational research, Cynbiose provides comprehensive services that include model development, pharmacology studies, and regulatory support to advance drug discovery and development. For more information, visit [www.cynbiose.com](http://www.cynbiose.com).

## **About Motac Neuroscience**

Motac Neuroscience is a leading research organisation dedicated to understanding and treating neurodegenerative diseases. Through innovative research and drug development, Motac Neuroscience aims to bring effective therapies to patients suffering from conditions such as Parkinson's and Alzheimer's disease. For more information, visit [www.motacneuroscience.com](http://www.motacneuroscience.com).

## **Media Contact:**

For Cynbiose:  
Erwan Corcuff  
CBO  
erwan.corcuff@cynbiose.com  
+33 608412186

For Motac Neuroscience:  
Leslie Largeais  
Community Manager  
leslie.largeais@motac.com  
+33 533 514 863